Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label active-controlled trial of semaglutide injection in Chinese adults with obesity
CTR20254198Phase 3Active
- Sponsor
- Hainan Zhonghe Pharmaceutical
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, Overweight, body weight control, sponsored by Hainan Zhonghe Pharmaceutical. Started Dec 2025; status: active.
02
Drugs
03
Conditions
obesityOverweightbody weight control
Beyond the preview
Go deeper on CTR20254198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254198.